pdufa.bio
Home › Decisions › IRON 2026-02-13

IRON FDA decision: Feb 13, 2026

Page updated ·next FDA decision on the calendar ·Data as of Oct 11, 2026 9:31 PM ET
The FDA's own letter · Complete Response Letter, NDA 220707 (PDF), dated February 13, 2026, released under FDA's CRL transparency program.
✕ COMPLETE RESPONSE LETTER

Disc Medicine Inc., Bitopertin · Erythropoietic Protoporphyria (EPP).

Run-up into the decision (T-120 → T+5)

PDUFA 2/13/26$94.11$59.418/29/25
Daily close, T-120 (8/29/25) through T+5. Run-up high $94.11 on 11/28/25, low $59.41 on 9/1/25 (T-120 to T-1). FDA decision 2/13/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-02-13
OutcomeCRL
Drug / candidateBitopertin - (BEACON)
CompanyDisc Medicine Inc.
120-day run-up (T-120→T-1)+18.7%

Every FDA approval letter and released Complete Response Letter we hold, by FDA action date: FDA approval letters.

Specialist biotech funds holding IRON, 13F for the quarter ended June 30, 2026

FundSharesValue at quarter endFiling
RA Capital Management2,450,221$179.2 millionfiled August 14, 2026
BVF Inc.1,153,612$84.4 millionfiled August 14, 2026
OrbiMed Advisors357,535$26.2 millionfiled August 14, 2026
Baker Bros. Advisors349,657$25.6 millionfiled August 14, 2026
RTW Investments30,000$2.2 millionfiled August 14, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

Was Bitopertin approved by the FDA?

Not in this review cycle. A Complete Response Letter, declining to approve the application for Bitopertin in its current form, was announced on February 13, 2026. A CRL is not final; the primary source is linked on this page.

Which company is behind Bitopertin?

Bitopertin is a Disc Medicine Inc. (IRON) program. The company announced the FDA decision on February 13, 2026; the FDA's own record of the decision is linked on this page.

How did IRON stock trade into the FDA decision?

Measured over the 120 trading days before the decision (T-120 to T-1), IRON moved +18.7%. That is the recorded price path into this specific event. Historical measurement, not a prediction, and not investment advice.